Embryonic cell populations and methods to isolate such populations
AssigneeNational Jewish Center for Immunology and Respiratory Medicine
InventorsGordon M. Keller, Robert G. Hawley, Kyunghee Choi
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel immortalized precursor cell populations derived from embryonic stem cell populations and methods to produce such cell populations. Also disclosed is an assay to identify regulatory compounds capable of controlling cell growth for therapeutic and experimental use.
Claims23
A pluripotent cell population wherein said cell population is transformed with a HOX11 gene, and wherein said cell population differentiates into cellular lineages including primitive erythroid cells and definitive erythroid cells.
A HOX11 pluripotent precursor cell population, wherein said cell population is transformed with a HOX11 gene, and wherein said cell population differentiates into cellular lineages including primitive erythroid cells and definitive erythroid cells, and is responsive to a growth factor selected from the group consisting of interleukin-3, interleukin-4, interleukin-6, interleukin-11, erythropoietin, C-kit ligand, leukocyte inhibitory factor and mixtures thereof.
A HOX11 pluripotent precursor cell population, wherein said cell population is transformed with a HOX11 gene, and wherein said cell population differentiates into cellular lineages including primitive erythroid cells and definitive erythroid cells, and is responsive to a growth factor selected from the group consisting of interleukin-3, erythropoietin, C-kit ligand, leukocyte inhibitory factor and mixtures thereof.
A HOX11 precursor cell population which is transformed with a HOX11 gene and which expresses .beta.H1, .zeta. and .beta. major-globin RNA.
A HOX11 pluripotent precursor cell population, wherein said cell population is produced by the method comprising:
- a) introducing a HOX11 gene into an embryonic stem cell population to create a modified stem cell population;
- b) culturing said modified stem cell population from about 1 day to about 7 days in an embryoid body cell medium under effective conditions to produce a transformed embryoid body cell population;
- and
- c) incubating said transformed embryoid body cell population in the presence of a combination of growth factors selected from the group consisting of C-kit ligand combined with erythropoietin, and interleukin 3 combined with erythropoietin to obtain said pluripotent precursor cell is population.
Dependencies are inferred from the claim text.